ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01426009
Recruitment Status : Completed
First Posted : August 30, 2011
Results First Posted : May 7, 2018
Last Update Posted : May 9, 2018
Sponsor:
Information provided by (Responsible Party):
Sunovion Respiratory Development Inc.

Brief Summary:
The purpose of this study is to determine steady-state efficacy and dose response profile and to assess safety and pharmacokinetic profile of nebulized EP-101(SUN101) after 7-day dosing using an investigational high efficiency nebulizer (eFlow®) compared with placebo and two active comparators in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: EP-101 via nebulizer (eFlow®) 25 ug Drug: EP-101 via nebulizer (eFlow®) 50 ug Drug: EP-101 via nebulizer (eFlow®) 100 ug Drug: Placebo EP-101 Drug: Tiotropium bromide via (Spiriva® Handihaler®) Drug: Ipratropium bromide Inhalation Solution via Handihaler® DPI Drug: EP-101 via nebulizer (eFlow®) 200 ug Phase 2

Detailed Description:

This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, four-period, incomplete block design cross-over study using EP-101(SUN101) and open-label active controls (tiotropium bromide and ipratropium bromide). The study population will consist of subjects of 40-75 years of age with moderate to severe COPD. Approximately 133 subjects diagnosed with moderate to severe COPD will be enrolled in order to achieve minimum 105 subjects completing the study.

Following a run-in phase, each subject will be randomly assigned to one of 7 treatment sequences,(96 sequences when order of administration is considered), with each sequence comprised of four 7-day Treatment Periods. There will be a washout period of 7 days between each Treatment Period. Study visits will be conducted on Days 1 and 7 of each Treatment Period, with an overnight stay required in the clinic during these visits. A Final Study Visit will be conducted 7 days following the last study treatment.

During each Treatment Period, study treatments will be administered once daily (QD), except for ipratropium inhalation solution, which will be administered three times daily (TID). EP-101 (SUN101)active and placebo treatments will be administered using an investigational high-efficiency eFlow® nebulizer. Tiotropium bromide (Spiriva®) will be administered in an open-label manner via Handihaler® dry-powder inhaler (DPI). Ipratropium bromide inhalation solution will be administered in an open-label manner via general purpose nebulizer.

This study was previously posted by Elevation Pharmaceuticals, Inc. On September 5, 2012, Elevation was acquired by merger with Sunovion Pharmaceuticals Inc. ("Sunovion"), which resulted in Elevation becoming a direct wholly-owned subsidiary of Sunovion. In conjunction with this acquisition, the name of Elevation has been changed to Sunovion Respiratory Development Inc.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Seven Arm, Four-Period Cross-over, Incomplete Block Design, 7-Day Dosing Study to Assess the Dose-Response, Safety, and Efficacy of EP-101 (SUN101) in Subjects With Moderate to Severe COPD
Study Start Date : August 2011
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases
U.S. FDA Resources

Arm Intervention/treatment
Experimental: EP-101 via nebulizer (eFlow®) 25 ug
EP-101 via nebulizer (eFlow®)
Drug: EP-101 via nebulizer (eFlow®) 25 ug
EP-101 (25 ug ) Dose 1 administered once daily for 7 days
Other Name: SUN101
Active Comparator: Tiotropium bromide via (Spiriva® Handihaler®)
Tiotropium bromide via (Spiriva® Handihaler®)
Drug: Tiotropium bromide via (Spiriva® Handihaler®)
Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI
Other Name: Tiotropium bromide
Active Comparator: Ipratropium bromide Inhalation Solution
Ipratropium bromide Inhalation Solution via Handihaler® DPI
Drug: Ipratropium bromide Inhalation Solution via Handihaler® DPI
Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer
Other Name: Ipratropium bromide
Placebo Comparator: Placebo EP-101
Placebo
Drug: Placebo EP-101
Placebo EP-101 administered once daily for 7 days
Other Name: Placebo
Experimental: EP-101 via nebulizer (eFlow®) 50 ug
EP-101 via nebulizer (eFlow®)
Drug: EP-101 via nebulizer (eFlow®) 50 ug
EP-101 (50 ug ) administered once daily for 7 days
Other Name: SUN101
Experimental: EP-101 via nebulizer (eFlow®) 100 ug
EP-101 via nebulizer (eFlow®)
Drug: EP-101 via nebulizer (eFlow®) 100 ug
EP-101 (100ug) administered once daily for 7 days
Other Name: SUN101
Experimental: EP-101 via nebulizer (eFlow®) 200 ug
EP-101 via nebulizer (eFlow®)
Drug: EP-101 via nebulizer (eFlow®) 200 ug
EP-101 (200) ug administered once daily for 7 days
Other Name: SUN101



Primary Outcome Measures :
  1. Mean Change in 24 Post Dose Trough Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: Day 1 and Day 7 ]
    Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the mean of the spirometry values collected at 23 hours 30 minutes and 24 hours post dose for Day 1 and Day 7 within each Treatment Period. Baseline was calculated as the mean of the FEV1 values at 45 minutes and 15 minutes prior to the morning dose at Day 1 of each Treatment Period. Change from baseline was calculated as the trough FEV1 value minus the baseline for Day 1 and Day 7.

  2. Standardized Change in FEV1 Area Under the Curve (AUC) (0-12hr , 12-24hr, 0-24hr) on Day 1 and Day 7 [ Time Frame: Day 1 and Day 7 ]
    Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. The standardized FEV1 AUC(0-12hr and 12-24hr) on Day 1 and Day 7 was calculated using the trapezoidal rule from the changes in FEV1 at Day 1 and Day 7, respectively, from the baseline value (the mean of the two FEV1 values at 45 minutes and 15 minutes prior to morning dose at Day 1 of the respective Treatment Periods) and dividing by the actual length of the time interval.


Secondary Outcome Measures :
  1. Peak FEV1 (Maximum FEV1 During the First 4 Hours Post-dose on Day 1 and Day 7) [ Time Frame: Day 1 and Day 7 ]
    Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines

  2. Treatment Responders (Number of Subjects With Clinically Meaningful Change From Pre-dose in Trough FEV1 on Day 1 and Day 7) [ Time Frame: Day 1 and Day 7 ]
    Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Clinically meaningful is defined as when the change from baseline (mean of the two pre-dose values at Day 1) in 24 hour trough FEV1 on a SUN-101 treatment is more than 100 mL compared to the mean change in trough FEV1 from all subjects on the placebo treatment.

  3. Number of Participants With Adverse Events, Vital Signs, and Clinically Significant Abnormal ECG Values and Laboratory Tests [ Time Frame: Day 1 through Day 7 ]
    AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. Vital signs were performed during the screening period to confirm study eligibility and at the final study visit. ECGs were performed during the screening period to confirm study eligibility. Vital signs and ECG were additionally collected within 30 minutes pre-dose; and 30 minutes, and 1, 2, 4, 6, 12 hours, and 23 hours 45 minutes post-dose within each treatment period. Clinical laboratory assessments were conducted during the screening period, at each study visit during each treatment period, and at the final study visit.

  4. Rescue Medication Use [ Time Frame: Day 1 through Day 7 ]
    Mean number of puffs of daily rescue medication

  5. Treatment Responders (Percentage of Subjects With Clinically Meaningful Change From Pre-dose in Trough FEV1 on Day 1 and Day 7) [ Time Frame: Day 1 and Day 7 ]
    percentage of subjects with clinically meaningful change from pre-dose in trough FEV1 on Day 1 and Day 7 Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 40-75 years of age
  • Clinical diagnosis of moderate to severe COPD
  • Current/ex-smokers with at least 10 pack-year smoking history
  • Post-bronchodilator FEV1 ≥ 30% and ≤ 70% predicted normal values
  • Post-bronchodilator FEV1/FVC ratio of ≤ 0.70
  • Post-bronchodilator improvement in FEV1 ≥ 12% and ≤ 30%, and a minimum of 100 mL
  • Willing and able to remain at the study site for at least 24 hours at each study visit
  • Signed written informed consent

Exclusion Criteria:

  • Current evidence or recent history of any clinically significant and unstable disease or abnormality (e.g., myocardial infarction, cardiac failure, uncontrolled hypertension, life-threatening arrhythmias, uncontrolled diabetes)
  • Primary diagnosis of asthma
  • History of malignancy within the past 5 years
  • History of COPD exacerbation within 6 weeks of Screening
  • Daily oxygen therapy > 10 hours per day
  • Systemic steroids use within 6 weeks of Screening
  • Respiratory tract infection within 6 weeks of Screening
  • History of tuberculosis, bronchiectasis
  • History of urinary retention or bladder neck obstruction type symptoms
  • History of glaucoma
  • Prolonged QTc interval (>460msec) or history of long QT syndrome
  • Recent history of alcohol or drug abuse
  • Females who are pregnant or breastfeeding, or if of child-bearing potential unwilling to practice acceptable birth control methods
  • History of hypersensitivity or intolerance to aerosol medications
  • Participation in another investigational drug study within 30 days of Screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01426009


Locations
United States, Arizona
Elevation Investigational Site
Phoenix, Arizona, United States, 85006
United States, California
Elevation Investigational Site
Los Angeles, California, United States, 90048
United States, Florida
Elevation Investigational Site
DeLand, Florida, United States, 32720
United States, Kentucky
Elevation Investigational SIte
Madisonville, Kentucky, United States, 42431
United States, Massachusetts
Elevation Investigational Site
North Dartmouth, Massachusetts, United States, 02747
United States, North Carolina
Elevation Investigational Site
Charlotte, North Carolina, United States, 28207
Elevation Investigational Site
Raleigh, North Carolina, United States, 27607
United States, Oregon
Elevation Investigational Site
Medford, Oregon, United States, 97504
United States, South Carolina
Elevation Investigational Site
Spartanburg, South Carolina, United States, 29303
United States, Washington
Elevation Investigational Site
Tacoma, Washington, United States, 98418
United Kingdom
Elevation Investigational Site
Manchester, United Kingdom, M21 8AD
Sponsors and Collaborators
Sunovion Respiratory Development Inc.
Investigators
Study Director: Ahmet Tutuncu, M.D., Ph.D. Chief Medical Officer / Elevation Pharmaceuticals, Inc.

Responsible Party: Sunovion Respiratory Development Inc.
ClinicalTrials.gov Identifier: NCT01426009     History of Changes
Other Study ID Numbers: EP-101-03
First Posted: August 30, 2011    Key Record Dates
Results First Posted: May 7, 2018
Last Update Posted: May 9, 2018
Last Verified: May 2018

Keywords provided by Sunovion Respiratory Development Inc.:
COPD

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Pharmaceutical Solutions
Tiotropium Bromide
Ipratropium
Bromides
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anticonvulsants